COPD alliance with Roche could be worth more than €400 million to Galapagos
This article was originally published in Scrip
Executive Summary
Galapagos and Roche have signed a research agreement covering potential new therapies for chronic obstructive pulmonary disease (COPD) which could be worth more than €400 million to the Belgian biotech firm if Roche licenses and commercialises resulting products.